Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
19 evidence topics · 19 sources
Treat-to-target strategy: National Psoriasis Foundation Delphi consensus on instrument and evaluation timing
“The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 25 psoriasis experts participated in the Delphi process.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most preferred instrument was body surface area (BSA).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most preferred time for evaluating patient response after starting new therapies was at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During the maintenance period, evaluation every 6 months was most preferred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment goal monitoring and therapy modification: guideline
“Various forms of adjustment include increasing the dosage, initiation of combination therapy, or transitioning to another drug or procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment goals must be determined individually with the patients in a joint decision‐making process.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During maintenance therapy, control of treatment goals should be done at the same intervals as the general monitoring, usually every 8 to 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tuberculosis screening before and during biologic or deucravacitinib therapy: guideline
“A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend excluding latent TB infection using interferon‐gamma release assay (IGRA) before initiating treatment with a biologic agent or deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Deucravacitinib: due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against repeating IGRA just based on fixed time intervals or due to switching from one drug to another without relevant risk of exposure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend repeating IGRA during treatment if there is an increased risk of TB exposure (see background text: Indications for an increased probability of an exposure risk).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Latent tuberculosis testing for IL-17 and IL-23 inhibitors: NPF and IPC joint position
“Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“87.5% of the members from the National Psoriasis Foundation Medical Board and International Psoriasis Council approved a new Joint Position Statement regarding psoriasis patients being treated with IL-17 or IL-23 inhibitors, stating that testing for latent TB infection is not required.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psoriasis experts reached consensus that routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tuberculosis testing requirement removed for risankizumab and absent for icotrokinra
Hepatitis B and hepatitis C screening before systemic therapy: guideline
“We recommend screening patients for hepatitis B (HBsAg, anti‐HBs, anti‐HBc) as a routine measure before starting a treatment with ciclosporin, deucravacitinib, methotrexate, or biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest screening patients for hepatitis C as a routine measure before starting a treatment with deucravacitinib, methotrexate, or biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend against screening for hepatitis A, D, or E as a routine measure before starting a systemic treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If viral hepatitis has been excluded once before initiating an immunosuppressive therapy and there is no history‐related/laboratory evidence of infection, re‐testing is not required when changing the therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pretreatment workup for deucravacitinib: guideline expert recommendations
“Check need for vaccinations according to current vaccination recommendations including prophylactic vaccination against herpes zoster” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inform patients to discontinue treatment and present for examination if they experience muscle weakness or pain, especially if these are accompanied by fatigue or fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Not all tests may be required for all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The recommendations are based on expert opinions and take into account that the experience with the drug is still limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vaccination timing and live vaccines during oral and biologic therapy
“The optimal time for vaccinations is before starting a systemic immunosuppressive therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, inactivated vaccines can be used safely in patients receiving systemic immunosuppressive therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity screening: psoriatic arthritis at each visit and cardiovascular risk assessment
Telemedicine management of psoriasis
“Telemedicine utilization among dermatologists increased from under 15% to >95% after the pandemic, reflecting its marked popularity among patients and uptake for physicians.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As compared with in-person care, collaborative and efficient teledermatology models equivalently improve PASI scores, BSA, and dermatology life quality index.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Teledermatology is a reasonable alternative for providing long-term management of patients with psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to guarantee the accessibility of in-person care for patients with psoriasis and ensure that telemedicine does not supplant such availability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PEST should be provided to patients every 6 months to screen for PsA to help mitigate the undertreatment and delay in the diagnosis of this common comorbidity in patients with psoriasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Online and in-person care: 12-month randomized equivalency trial in 296 adults
“Overall, 296 adults with physician-diagnosed psoriasis from ambulatory clinics were randomly assigned to either online or in-person care; all were analyzed for outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across 12 months, for the online group, the mean ± standard deviation decline in Skindex-16 from baseline across follow-up visits was 9.02 ± 20.67 compared with 10.55 ± 23.50 for the in-person group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over the 12-month study period, the in-person group had a total of 315 in-person visits; the online group had 161 online visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Shared decision-making aid for biologic choice: dosing interval by agent
| Agent | How often do I need to inject the treatment? |
|---|---|
| Adalimumab | “Every other week” |
| Certolizumab pegol | “Every 2 weeks” |
| Etanercept | “Once or twice a week” |
| Infliximab | “Every 8 weeks” |
| Ustekinumab | “Every 12 weeks” |
| Bimekizumab | “Every 8 weeks” |
| Brodalumab | “Every 2 weeks” |
| Ixekizumab | “Every 4 weeks” |
| Secukinumab | “Every month” |
| Guselkumab | “Every 8 weeks” |
| Risankizumab | “Every 12 weeks” |
| Tildrakizumab | “Every 12 weeks” |
Pharmacy-led prior authorization management in dermatology
“Biologic agents (55.2%) and brand-name only medications (42.8%) required PA at higher rates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacy intervention resulted in shorter time to PA submission (4 days vs 1 day, P < .001) and decision (6 days vs 1 day, P < .001) and higher approval rates (63.9% vs 80.6%, P < .001) but did not decrease the total number of PAs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with approved PAs had higher likelihood of disease improvement vs those with denied PAs (71.1% vs 58.0%, P = .013).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Online prescription management and specialty pharmacy support: abandonment and time to first fill
“HCPro patients had a lower abandonment rate (6.4% vs. 13.9%; P < 0.001) and reduced days to prescription fill (7.0 vs. 14.4; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After controlling for baseline characteristics, abandonment odds were 43% lower for patients using HCPro (odds ratio = 0.57; P = 0.004).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence interventions including pharmacist-delivered models: systematic review of 26 studies
“Twenty-six studies were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Digital and technology‐supported interventions, including mobile applications, short message service reminders and electronic monitoring‐supported platforms were the most frequently evaluated and were generally associated with modest improvements in adherence when compared to usual care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare professional‐led interventions such as nurse and pharmacist delivered models demonstrated potential benefits in adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across studies, improvements in adherence were more consistently observed than improvements in clinical severity and quality‐of‐life outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Step therapy before specialty medication: time to second referral in psoriasis and atopic dermatitis
“The included patients (N = 83) were predominantly White (75%) and female (61%) with a median age of 50 years (interquartile range [IQR] = 37-61 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“62 patients were required to use step therapy, and 21 were required to use a formulary alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients required to use step therapy, 37 (60%) had a second referral for a specialty medication because of failing step therapy requirements, with a median time to a second referral of 75 days (IQR = 27-135).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior authorization burden, approval rates, and wait times for biologics
“In September 2016, 626 PAs were generated from 9512 patient encounters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Records from the University of Miami Health System were reviewed, and 101 patients were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with Medicare had the shortest wait time with a mean of 7.3 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Private insurance patients waited the longest, regardless of whether they had a PPO (37 days) or HMO (41.3 days).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
German S3 guideline adapted from EuroGuiDerm, part 2: specific clinical and comorbid situations
“S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote